CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. 2013

Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
Department of Urology, Örebro University Hospital, Örebro, Sweden. sabina.davidsson@orebroll.se

Prostate cancer represents a major contributor to cancer mortality, but the majority of men with prostate cancer will die of other causes. Thus, a challenge is identifying potentially lethal disease at diagnosis. Conflicting results have been reported when investigating the relationship between infiltration of lymphocytes and survival in prostate cancer. One of the mechanisms suggested is the recruitment of regulatory T cells (T(regs)), a subpopulation of T cells that have a role in promoting tumor growth. T(regs) counteract tumor rejection through suppressive functions on the anti-immune response but their prognostic significance is still unknown. We report here the results of a conducted case-control study nested in a cohort of men treated with transurethral resection of the prostate and diagnosed incidentally with prostate cancer. Cases are men who died of prostate cancer (n=261) and controls are men who survived >10 years after their diagnosis (n=474). Infiltration of both T(helper) and T(cytotoxic) cells was frequently observed and the majority of the T(regs) were CD4(+). T(helper) or T(cytotoxic) cells were not associated with lethal prostate cancer. However, we found a nearly twofold increased risk of lethal prostate cancer when comparing the highest with the lowest quartile of CD4(+) T(regs) cells (95% confidence interval: 1.3-2.9). Our conclusion is that men with greater numbers of CD4(+) T(regs) in their prostate tumor environment have an increased risk of dying of prostate cancer. Identification of CD4(+) T(regs) in tumor tissue may predict clinically relevant disease at time of diagnosis independently of other clinical factors.

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
December 2007, Clinical cancer research : an official journal of the American Association for Cancer Research,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
April 2018, Annual review of immunology,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
May 2011, Immunotherapy,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
September 2018, Iranian journal of immunology : IJI,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
September 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
January 2012, Nature communications,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
March 2011, European journal of immunology,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
February 2018, Journal of cellular biochemistry,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
December 2018, Iranian journal of allergy, asthma, and immunology,
Sabina Davidsson, and Anna-Lena Ohlson, and Swen-Olof Andersson, and Katja Fall, and Allison Meisner, and Michelangelo Fiorentino, and Ove Andrén, and Jennifer R Rider
February 2001, Clinical immunology (Orlando, Fla.),
Copied contents to your clipboard!